Goldstein Advisors LLC Sells 1,092 Shares of Zoetis Inc. $ZTS

Goldstein Advisors LLC lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 45.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,288 shares of the company’s stock after selling 1,092 shares during the quarter. Goldstein Advisors LLC’s holdings in Zoetis were worth $201,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Swmg LLC boosted its stake in shares of Zoetis by 19.3% during the 2nd quarter. Swmg LLC now owns 1,884 shares of the company’s stock worth $284,000 after acquiring an additional 305 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Zoetis during the 2nd quarter worth about $11,104,000. Novare Capital Management LLC boosted its stake in shares of Zoetis by 0.5% during the 2nd quarter. Novare Capital Management LLC now owns 96,171 shares of the company’s stock worth $14,998,000 after acquiring an additional 501 shares in the last quarter. Quotient Wealth Partners LLC boosted its stake in shares of Zoetis by 38.6% during the 2nd quarter. Quotient Wealth Partners LLC now owns 4,391 shares of the company’s stock worth $685,000 after acquiring an additional 1,224 shares in the last quarter. Finally, Stanley Laman Group Ltd. boosted its stake in shares of Zoetis by 11.3% during the 2nd quarter. Stanley Laman Group Ltd. now owns 1,977 shares of the company’s stock worth $308,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.6%

Zoetis stock opened at $144.15 on Monday. The business has a 50 day moving average price of $148.73 and a two-hundred day moving average price of $153.65. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market cap of $63.88 billion, a price-to-earnings ratio of 24.81, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $193.49.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio is 34.42%.

Analyst Ratings Changes

Several research firms recently weighed in on ZTS. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Argus reissued a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.